|
|
||||||||


* Department of Medicine, Harvard Thorndike Laboratories, Charles A. Dana Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; and
Pulmonary Center, Boston University School of Medicine, Boston, MA 02118
Human eosinophils are potential sources of inflammatory and immunomodulatory mediators, including cysteinyl leukotrienes, chemokines, and cytokines, which are pertinent to allergic inflammation. We evaluated the means by which IL-16, a recognized eosinophil chemoattractant, might act on eosinophils to affect their capacity to release leukotriene C4 (LTC4) or their preformed stores of chemokines (eotaxin, RANTES) or Th1 (IL-12) or Th2 (IL-4) cytokines. IL-16 dose dependently (0.01100 nM) elicited new lipid body formation, intracellular LTC4 formation at lipid bodies, and priming for enhanced calcium ionophore-activated LTC4 release. IL-16 also elicited brefeldin A-inhibitable, vesicular transport-mediated release of preformed IL-4, but not IL-12, from eosinophils. CD4 is a recognized IL-16R, and accordingly anti-CD4 Fab, soluble CD4, and a CD4 domain 4-based IL-16 blocking peptide inhibited the actions of IL-16 on eosinophils. Although CD4 is not G-protein coupled, pertussis toxin inhibited IL-16-induced eosinophil activation. IL-16 actions were found to be mediated by the autocrine activity, not of platelet-activating factor, but rather of endogenous CCR3-acting chemokines. IL-16 induced the rapid vesicular transport-mediated release of RANTES. The effects of IL-16 were blocked by CCR3 inhibitors (met-RANTES, anti-CCR3 mAb) and by neutralizing anti-eotaxin and anti-RANTES mAbs, but not by platelet-activating factor receptor antagonists (CV6209, BN52021). RANTES and eotaxin each enhanced LTC4 and IL-4 (but not IL-12) release. Therefore, IL-16 activation of eosinophils is CD4-mediated to elicit the extracellular release of preformed RANTES and eotaxin, which then in an autocrine fashion act on plasma membrane CCR3 receptors to stimulate both enhanced LTC4 production and the preferential release of IL-4, but not IL-12, from within eosinophils.
This article has been cited by other articles:
![]() |
D. S. Green, D. M. Center, and W. W. Cruikshank Human Immunodeficiency Virus Type 1 gp120 Reprogramming of CD4+ T-Cell Migration Provides a Mechanism for Lymphadenopathy J. Virol., June 1, 2009; 83(11): 5765 - 5772. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Chou, J.-Y. Weng, H.-L. Lai, F. Liao, S. H. Sun, P.-H. Tu, D. W. Dickson, and Y. Chern Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes J. Neurosci., March 26, 2008; 28(13): 3277 - 3290. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Moqbel and J. J. Coughlin Differential Secretion of Cytokines Sci. Signal., June 6, 2006; 2006(338): pe26 - pe26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Gianoukakis, R. S. Douglas, C. S. King, W. W. Cruikshank, and T. J. Smith Immunoglobulin G from Patients with Graves' Disease Induces Interleukin-16 and RANTES Expression in Cultured Human Thyrocytes: A Putative Mechanism for T-Cell Infiltration of the Thyroid in Autoimmune Disease Endocrinology, April 1, 2006; 147(4): 1941 - 1949. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. Mesquita-Santos, A. Vieira-de-Abreu, A. S. Calheiros, I. H. Figueiredo, H. C. Castro-Faria-Neto, P. F. Weller, P. T. Bozza, B. L. Diaz, and C. Bandeira-Melo Cutting Edge: Prostaglandin D2 Enhances Leukotriene C4 Synthesis by Eosinophils during Allergic Inflammation: Synergistic In Vivo Role of Endogenous Eotaxin J. Immunol., February 1, 2006; 176(3): 1326 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Qi, J. Wang, S. Mandadi, K. Tanaka, B. D. Roufogalis, M. C. Madigan, K. Lai, F. Yan, B. H. Chong, R. L. Stevens, et al. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor Blood, January 1, 2006; 107(1): 135 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ferland, N. Flamand, F. Davoine, J. Chakir, and M. Laviolette IL-16 Activates Plasminogen-Plasmin System and Promotes Human Eosinophil Migration into Extracellular Matrix via CCR3-Chemokine-Mediated Signaling and by Modulating CD4 Eosinophil Expression J. Immunol., October 1, 2004; 173(7): 4417 - 4424. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Gianoukakis, L. J. Martino, N. Horst, W. W. Cruikshank, and T. J. Smith Cytokine-Induced Lymphocyte Chemoattraction from Cultured Human Thyrocytes: Evidence for Interleukin-16 and Regulated upon Activation, Normal T Cell Expressed, and Secreted Expression Endocrinology, July 1, 2003; 144(7): 2856 - 2864. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pritchard, R. Han, N. Horst, W. W. Cruikshank, and T. J. Smith Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves' Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway J. Immunol., June 15, 2003; 170(12): 6348 - 6354. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bandeira-Melo, L. J. Woods, M. Phoofolo, and P. F. Weller Intracrine Cysteinyl Leukotriene Receptor-mediated Signaling of Eosinophil Vesicular Transport-mediated Interleukin-4 Secretion J. Exp. Med., September 16, 2002; 196(6): 841 - 850. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |